MedTrace Logo

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

NCT05692596 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 317

Last updated 2026-04-01

No results posted yet for this study

Summary

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

Conditions

  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cyst
  • Chronic Pancreatitis
  • Fatty Pancreas
  • Genetic Pancreatic Cancer
  • Genetic Pancreatitis
  • BRCA Mutation
  • Lynch Syndrome
  • FAP
  • Familial Atypical Multiple Mole-Melanoma
  • PALB2 Gene Mutation
  • Peutz-Jeghers Syndrome
  • Ataxia Telangiectasia

Interventions

OTHER

Data collection

Investigators will compile data typically collected clinically. This data will include demographics, cancer screening procedures, cancer diagnosis and staging, chemotherapy, immunotherapy, radiation therapy, surgery, comorbidities, medication use, lifestyle and other cancer risk factors, quality of life, vital status, and molecular data generated from specimens collected clinically.

Sponsors & Collaborators

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Shaffer Mok, MD, MBS · Moffitt Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-06
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05692596 on ClinicalTrials.gov